Complete Pathologic Response to Gemcitabine and Oxaliplatin Chemotherapy After Prior Therapies in a Patient With Hepatocellular Carcinoma and Peritoneal Metastases Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Overview

Journal World J Oncol

Specialty Oncology

Date 2024 May 16

PMID 38751709

Authors

Amry Majeed

Sneha Alaparthi

Dina Halegoua-DeMarzio

Jaime Eberle-Singh

Wei Jiang

Pramila Rani Anne

Ashesh P Shah

Wilbur B Bowne

Daniel Lin

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is often diagnosed at a late stage and frequently recurs despite curative intervention, leading to poor survival outcomes. Frontline systemic therapies include combination immunotherapy regimens and tyrosine kinase inhibitors. We report a case of a 38-year-old woman with chronic hepatitis B and C coinfection-associated non-cirrhotic HCC, which recurred in the peritoneum after initial resection of her primary tumor. Disease progression occurred on both atezolizumab/bevacizumab and lenvatinib, and she was subsequently treated with gemcitabine and oxaliplatin (GEMOX) chemotherapy and exhibited a profound clinical response on imaging with normalization of alpha fetoprotein (AFP) after several months. Following extensive multidisciplinary discussion, she underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) that removed all visible macroscopic tumor. Her pathology demonstrated a complete pathologic response. She received two additional months of postoperative chemotherapy, and then proceeded with close monitoring off therapy. To our knowledge, this is the first reported case of a complete pathologic response to GEMOX chemotherapy in the context of CRS/HIPEC for peritoneal metastases in HCC, after progression on standard immunotherapy and tyrosine kinase inhibitor treatments. In this report, we review the current systemic treatment landscape in HCC. We highlight potential consideration of cytotoxic chemotherapy, which is less frequently utilized in current practice, in selected patients with HCC, and discuss the role of CRS/HIPEC in the management of peritoneal metastases. Further investigation regarding predictors of response to systemic treatments is strongly needed. Multidisciplinary management may ultimately prolong survival in patients with advanced HCC.

References

Kelley R, Ryoo B, Merle P, Park J, Bolondi L, Chan S . Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020; 5(4). PMC: 7451459. DOI: 10.1136/esmoopen-2020-000714. View

Abou-Alfa G, Meyer T, Cheng A, El-Khoueiry A, Rimassa L, Ryoo B . Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1):54-63. PMC: 7523244. DOI: 10.1056/NEJMoa1717002. View

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

Brown T, Mamtani R, Gimotty P, Karasic T, Yang Y . Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis. J Cancer Res Clin Oncol. 2023; 149(6):2345-2354. PMC: 11044531. DOI: 10.1007/s00432-023-04590-9. View

Jacquet P, Sugarbaker P . Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996; 82:359-74. DOI: 10.1007/978-1-4613-1247-5_23. View

Zhu A, Finn R, Mulcahy M, Gurtler J, Sun W, Schwartz J . A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013; 19(23):6614-23. PMC: 4795808. DOI: 10.1158/1078-0432.CCR-13-1442. View

van Der Speeten K, Stuart O, Chang D, Mahteme H, Sugarbaker P . Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2010; 68(1):147-56. DOI: 10.1007/s00280-010-1460-4. View

da Silva R, Sugarbaker P . Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006; 203(6):878-86. DOI: 10.1016/j.jamcollsurg.2006.08.024. View

Ronnett B, Yan H, Kurman R, Shmookler B, Wu L, Sugarbaker P . Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer. 2001; 92(1):85-91. DOI: 10.1002/1097-0142(20010701)92:1<85::aid-cncr1295>3.0.co;2-r. View

10.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

11.

Fan Y, Xue H, Zheng H . Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. J Hepatocell Carcinoma. 2022; 9:233-263. PMC: 8977221. DOI: 10.2147/JHC.S358082. View

12.

Zhu A, Abbas A, Ruiz de Galarreta M, Guan Y, Lu S, Koeppen H . Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022; 28(8):1599-1611. DOI: 10.1038/s41591-022-01868-2. View

13.

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S . Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2014; 261(5):947-55. DOI: 10.1097/SLA.0000000000000710. View

14.

Zaanan A, Williet N, Hebbar M, Dabakuyo T, Fartoux L, Mansourbakht T . Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2012; 58(1):81-8. DOI: 10.1016/j.jhep.2012.09.006. View

15.

Qin S, Bai Y, Lim H, Thongprasert S, Chao Y, Fan J . Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013; 31(28):3501-8. DOI: 10.1200/JCO.2012.44.5643. View

16.

Ceelen W, Flessner M . Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2009; 7(2):108-15. DOI: 10.1038/nrclinonc.2009.217. View

17.

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

18.

Kow A, Kwon C, Song S, Kim J, Joh J . Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma in a tertiary institution. Surgery. 2015; 157(4):645-53. DOI: 10.1016/j.surg.2014.07.024. View

19.

Dong Y, Wong J, Sugimura R, Lam K, Li B, Kwok G . Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers (Basel). 2021; 13(8). PMC: 8072916. DOI: 10.3390/cancers13081949. View

20.

Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. View